Diagnostics.ai

Executive Summary

Diagnostics.ai, founded in 2016 and headquartered in London, UK, is a pioneering biotech company that leverages artificial intelligence to transform PCR-based diagnostic workflows. Its flagship platform, pcr.ai, is a CE-IVDR certified software solution that automates the analysis, quality control, and reporting of PCR test data, reducing hands-on time and improving accuracy. By integrating seamlessly with existing laboratory instruments and information systems, the platform enables labs to standardize processes and enhance throughput. The company’s focus on addressing inefficiencies in molecular diagnostics positions it well in a growing market driven by increasing demand for faster, more reliable testing in infectious disease and genomics. Diagnostics.ai has already secured adoption among leading healthcare institutions across Europe, demonstrating the clinical utility of its AI-powered approach. The company’s key differentiator lies in its ability to reduce human error and turnaround times while maintaining regulatory compliance. With the global diagnostics market expanding and a shift toward digitalization in labs, Diagnostics.ai is well-placed for further growth. Potential catalysts include US market entry via FDA clearance, strategic partnerships with diagnostic instrument manufacturers, and expanded AI capabilities for variant detection. The company’s low-profile status and undiluted focus on PCR analytics suggest significant upside if it can capture share in the competitive but fragmented lab automation market.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for pcr.ai60% success
• Q2 2026Strategic partnership with a major diagnostics OEM70% success
• Q3 2026Launch of AI-powered variant detection module80% success